{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'or not surgically sterile [absence of ovaries and/or uterus]) must have a negative serum', 'pregnancy test at Screening and negative urine pregnancy tests at all protocol-specified', 'timepoints (i.e., prior to each dose and through Week 48 of the Follow-Up Period);', 'subjects who are sexually active with a non-vasectomized male partner must agree to use', '2 reliable forms of contraception during the trial, one of which is recommended to be', 'hormonal, such as an oral contraceptive. Hormonal contraception must be started at least', 'one full cycle prior to Baseline and continue for 180 days after the last dose of study', 'drug. Highly effective contraceptive methods (with a failure rate less than 1% per year),', 'when used consistently and correctly, includes implants, injectables, combined oral', 'contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized', 'partner.', '11. Male subjects must be surgically sterile or, if sexually active with a female partner of', 'childbearing potential, must agree to use a barrier contraceptive method from Screening', 'through 180 days after the last dose of study drug.', '12. Subject is willing and able to comply with the prescribed treatment protocol and', 'evaluations for the duration of the study.', '9.3.2 Exclusion Criteria', 'Subjects will be ineligible for study participation if they meet any of the following criteria:', '1. Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease', 'in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary', 'to optic nerve involvement within the last 6 months.', '2.', 'Corneal decompensation unresponsive to medical management.', '3. Decrease in CAS of > 2 points in the study eye between Screening and Baseline.', '4. Decrease in proptosis of > 2 mm in the study eye between Screening and Baseline.', '5. Previous orbital irradiation or surgery for TED.', '6.', 'Any steroid use (intravenous [IV] or oral) with a cumulative dose equivalent to > 1 g of', 'methylprednisolone for the treatment of TED. Previous steroid use (IV or oral) with a', 'cumulative dose of <1 g methylprednisolone or equivalent for the treatment of TED and', 'previous use of steroid eye drops is allowed if discontinued at least 4 weeks prior to', 'Screening.', '7. Corticosteroid use for conditions other than TED within 4 weeks prior to Screening', '(topical steroids for dermatological conditions and inhaled steroids are allowed).', '8. Selenium and biotin must be discontinued 3 weeks prior to Screening and must not be', 'restarted during the clinical trial; however, taking a multivitamin that includes selenium', 'and/or biotin is allowed.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 67 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.', 'Any previous treatment with rituximab (Rituxan\u00ae or Mab Thera', 'or tocilizumab', '(Actemra or Roactemra). Use of any other non-steroid immunosuppressive agent', 'within 3 months prior to Screening.', '10. Use of an investigational agent for any condition within 60 days prior to Screening or', 'anticipated use during the course of the trial.', '11. Identified pre-existing ophthalmic disease that, in the judgment of the Investigator, would', 'preclude study participation or complicate interpretation of study results.', '12. Bleeding diathesis that in the judgment of the Investigator would preclude inclusion in', 'the clinical trial.', '13. Malignant condition in the past 12 months (except successfully treated basal/squamous', 'cell carcinoma of the skin).', '14. Pregnant or lactating women.', '15. Current drug or alcohol abuse, or history of either within the previous 2 years, in the', 'opinion of the Investigator or as reported by the subject.', '16. Biopsy-proven or clinically suspected IBD (e.g., diarrhea with or without blood or rectal', 'bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or', 'incontinence for more than 4 weeks without a confirmed alternative diagnosis OR', 'endoscopic or radiologic evidence of enteritis/colitis without a confirmed alternative', 'diagnosis).', '17. Known hypersensitivity to any of the components of teprotumumab or prior', 'hypersensitivity reactions to mAbs.', '18. Any other condition that, in the opinion of the Investigator, would preclude inclusion in', 'the study.', '19. Previous enrollment in this study or participation in a prior teprotumumab clinical trial.', '20. HIV, hepatitis C or hepatitis B infections.', '9.3.3 Removal of Subjects from Therapy or Assessment', 'All subjects are free to withdraw from study participation at any time, for any reason, and', 'without prejudice to their further medical care. In addition, the Investigator may terminate a', 'subject from the study at any time. The primary reason for discontinuation from the study and/or', 'study drug should be recorded on the eCRF using one of the following categories:', 'Adverse Event. The subject experiences an AE that imposes an unacceptable risk to the', \"subject's health, or the subject is unwilling to continue because of an AE. AEs requiring\", 'permanent study drug discontinuation per the protocol include:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 68 of 117']\n\n###\n\n", "completion": "END"}